SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-0.77%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$595M
AUM Growth
+$595M
(-9.3%)
Cap. Flow
-$59.9M
Cap. Flow
% of AUM
-10.06%
Top 10 Holdings %
Top 10 Hldgs %
57.86%
Holding
38
New
10
Increased
10
Reduced
16
Closed
2
Top Buys
| 1 |
Merck
MRK
|
$31.4M |
| 2 |
AGN
Allergan plc
AGN
|
$10.2M |
| 3 |
Cigna
CI
|
$8.08M |
| 4 |
DaVita
DVA
|
$6.26M |
| 5 |
Boston Scientific
BSX
|
$5.75M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$47.8M |
| 2 |
Baxter International
BAX
|
$15.5M |
| 3 |
SHPG
Shire pic
SHPG
|
$14.7M |
| 4 |
Elevance Health
ELV
|
$13.8M |
| 5 |
Abbott
ABT
|
$11M |
Sector Composition
| 1 | Healthcare | 97.59% |
| 2 | Industrials | 0.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Abbott
ABT
$231B
| $61.6M | 10.36% |
1,079,842
-191,900
| -15% | -$11M |
|
|
2
Baxter International
BAX
$12.7B
| $44.9M | 7.55% |
694,438
-239,695
| -26% | -$15.5M |
|
|
3
Boston Scientific
BSX
$156B
| $42.2M | 7.09% |
1,700,880
+232,000
| +16% | +$5.75M |
|
4
Revvity
RVTY
$10.5B
| $32.2M | 5.42% |
440,808
-100,800
| -19% | -$7.37M |
|
|
5
Merck
MRK
$210B
| $31.4M | 5.28% |
+558,500
| New | +$31.4M |
|
6
AstraZeneca
AZN
$248B
| $31.1M | 5.23% |
896,771
+156,100
| +21% | +$5.42M |
|
|
7
Elevance Health
ELV
$71.8B
| $27.3M | 4.59% |
121,310
-61,300
| -34% | -$13.8M |
|
8
Gilead Sciences
GILD
$140B
| $25.6M | 4.31% |
357,890
+22,200
| +7% | +$1.59M |
|
9
Integra LifeSciences
IART
$1.18B
| $24.2M | 4.08% |
506,630
-22,600
| -4% | -$1.08M |
|
10
Bristol-Myers Squibb
BMY
$96B
| $23.6M | 3.97% |
385,006
-74,600
| -16% | -$4.57M |
|
11
Bio-Rad Laboratories Class A
BIO
$8.06B
| $22.7M | 3.81% |
95,040
-14,400
| -13% | -$3.44M |
|
12
Perrigo
PRGO
$3.27B
| $21.8M | 3.66% |
249,540
-29,900
| -11% | -$2.61M |
|
13
Biogen
BIIB
$19.4B
| $21M | 3.52% |
65,800
-18,200
| -22% | -$5.8M |
|
14
Ironwood Pharmaceuticals
IRWD
$214M
| $17.8M | 2.99% |
1,188,553
-636,449
| -35% | -$9.54M |
|
|
NUVA
15
DELISTED
NuVasive, Inc.
NUVA
| $15.2M | 2.56% |
260,200
+77,200
| +42% | +$4.52M |
|
|
16
Cigna
CI
$80.3B
| $14.9M | 2.5% |
73,170
+39,800
| +119% | +$8.08M |
|
|
17
Eli Lilly
LLY
$657B
| $13M | 2.18% |
153,414
-566,132
| -79% | -$47.8M |
|
18
Labcorp
LH
$23.1B
| $12.8M | 2.14% |
80,000
+10,000
| +14% | +$1.6M |
|
|
PDCO
19
DELISTED
Patterson Companies, Inc.
PDCO
| $11M | 1.84% |
303,132
-93,200
| -24% | -$3.37M |
|
20
McKesson
MCK
$85.4B
| $10.5M | 1.76% |
67,315
-51,785
| -43% | -$8.08M |
|
|
SHPG
21
DELISTED
Shire pic
SHPG
| $10.4M | 1.75% |
67,075
-95,081
| -59% | -$14.7M |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.3M | 1.73% |
150,992
+2,900
| +2% | +$197K |
|
|
AGN
23
DELISTED
Allergan plc
AGN
| $10.2M | 1.72% |
+62,600
| New | +$10.2M |
|
24
GSK
GSK
$79.9B
| $9.69M | 1.63% |
273,312
+136,657
| +100% | +$4.85M |
|
25
Lexicon Pharmaceuticals
LXRX
$400M
| $8.27M | 1.39% |
837,192
+99,739
| +14% | +$985K |
|